glp-1 trends Antagonists Increase Plan Drug Spend - What's Next GLP-1 Receptor Agonist Market Size

Retatrutide vs Survodutide: Triple vs Dual Agonist Comparison for Obesity and MASH Evidence-based comparison of retatrutide (GIP/GLP-1/glucagon triple agonist) and survodutide (GLP-1/glucagon dual agonist) for weight loss, MASH, and metabolic disease based on Phase 2 clinical trial data

Concerns about access extended across workplaces

Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital in Boston said patients ask her about microdosing "all the time." "(But) there are no studies showing what it does," she cautioned in a TODAY segment that aired on Nov

What is the Obesity GLP-1 Market Size

Enrollment increased by 1,057% to 347 in 2024 and reached 186 in the first 5 months of 2025

Durability of Results: Maintenance Studies: Tirzepatide (SURMOUNT-3): Continued treatment: Additional 5.5% weight loss Stopped treatment: Regained 14% of weight Conclusion: Need ongoing treatment Semaglutide (STEP-4): Continued treatment: Maintained loss, continued losing Stopped treatment: Regained most weight Conclusion: Need ongoing treatment Phentermine: FDA-approved for 12 weeks only Weight regain after stopping is universal Not a long-term solution All Weight Loss Medications: Obesity is chronic disease Medications treat symptoms, dont cure Stopping medication weight regain Long-term or indefinite use necessary for sustained results Safety Profile Comparison: Discontinuation Due to Side Effects: Tirzepatide: 6.2% Semaglutide: 6.9% Liraglutide: 9.9% Naltrexone-bupropion: 25% (very high) Orlistat: 15-20% Phentermine-topiramate: 8-10% GLP-1s have excellent tolerability considering their effectiveness